查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995452

荷爾蒙避孕藥市場：按類型、荷爾蒙成分、銷售管道和最終用戶分類－2026-2032年全球市場預測

Hormonal Contraceptives Market by Contraceptive Type, Hormonal Composition, Sales Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，荷爾蒙避孕藥市場價值將達到 186.5 億美元，到 2026 年將成長至 201.7 億美元，到 2032 年將達到 341.4 億美元，複合年成長率為 9.01%。

主要市場統計數據
基準年 2025 186.5億美元
預計年份：2026年 201.7億美元
預測年份 2032 341.4億美元
複合年成長率 (%) 9.01%

將影響荷爾蒙避孕藥市場的臨床、監管和主導因素置於具體情境中，以指導經營團隊決策和策略重點。

本報告引言概述了荷爾蒙避孕藥的現狀，從為高級相關人員量身定做的綜合觀點出發，分析了臨床創新、使用者偏好、監管趨勢和供應鏈複雜性。長效可逆避孕藥的進步，以及對避孕選擇和可及性的重新重視，重塑了臨床路徑和採購重點。同時，報銷政策的轉變和監管指南的不斷完善，也正在改變現有產品和新產品的核准時間和商業化路徑。

配方、管理系統、數位化照護路徑和以公平為中心的政策轉變方面的進步，正在全面重塑避孕藥具的提供和分發趨勢。

荷爾蒙避孕領域的變化是製劑、給藥方式和服務模式創新融合的結果，它正在改變人們獲取和獲得避孕服務的方式。隨著醫療服務提供者尋求減輕使用者負擔並提高用藥依從性，長效避孕藥正日益普及。同時，新一代製劑和新型給藥平台正努力平衡療效和耐受性。除了產品創新之外，醫療路徑的數位化和遠端醫療在處方開立方面的應用也正在拓展服務管道，重塑患者體驗，並改變傳統藥房和診所在啟動治療和後續觀察的作用。

本研究評估了美國2025年關稅政策的轉變將如何促進供應鏈多元化、區域生產投資和採購結構的調整。

美國2025年實施的關稅對避孕藥具供應鏈、採購慣例和商業重點產生了多方面的影響。關稅帶來的成本壓力迫使製造商和經銷商重新評估籌資策略，加快推進特定生產流程的本地化、供應商多元化以及重新談判供應商契約，以在不影響產品品質的前提下維持利潤率。因此，一些公司優先投資區域生產能力，並與供應商建立雙邊關係，以降低貿易政策變化帶來的風險。

將避孕藥類型、荷爾蒙成分、分銷管道和最終用戶環境聯繫起來的詳細細分觀點，為優先排序和商業化提供了指南。

市場區隔洞察揭示了產品屬性、荷爾蒙成分、分銷管道和終端用戶環境之間的交集，以及這些因素如何影響避孕產品的採納和方案設計。根據避孕方式的不同，市場包括植入、注射避孕藥、子宮內避孕器 (IUD)、口服避孕藥、經皮吸收貼片和陰道環。植入方面，雙桿和單桿設計導致不同的植入流程和對醫護人員的訓練要求。注射避孕藥則分為長效型Medroxyprogesterone製劑和庚酸型炔諾酮製劑，二者在給藥間隔和給藥環境方面有差異。口服避孕藥分為複方口服避孕藥和黃體素單藥製劑，二者在處方注意事項上有所不同。陰道環分為長期使用型和月用型，二者對用藥依從性和諮詢的影響也不同。

檢驗了美洲、歐洲、中東和非洲以及亞太地區的監管多樣性、採購模式以及數位技術的採用如何塑造差異化的戰略應對措施。

區域趨勢反映了不同的需求促進因素、法律規範和分銷挑戰，從而塑造了各區域的戰略重點。在美洲，支付方結構、公共衛生計畫和私人醫療服務提供者網路相互作用，影響部署模式和採購模式，尤其需要關注生殖健康政策的變化如何影響醫療服務的可近性和資金流動。歐洲、中東和非洲的監管環境呈現異質性，在這些地區，監管協調的努力與不同的報銷環境和基礎設施限制並存，這些因素影響產品選擇和部署策略。在亞太地區，快速的都市化、數位醫療的普及和不斷擴大的製造能力，在為企業應對不同的監管預期和當地市場准入要求時，既創造了商業性機遇，也帶來了營運上的複雜性。

產品差異化、夥伴關係策略和營運韌性如何決定老牌公司與新興避孕創新者之間的競爭。

競爭考察重點闡述了老牌製藥公司和新興專業公司在產品創新、供應鏈韌性和市場策略等領域的應對策略。主要企業正投資於改進配方和差異化給藥機制，以解決耐受性和依從性問題；而新參與企業和細分市場企業則專注於長效陰道環和新一代皮下植入式裝置等專業平台。夥伴關係與授權協議正成為加快產品上市速度、拓展產品系列且無需承擔全部研發成本的戰術性策略。

產業領導者應採取的切實可行的策略重點和營運措施，以使產品開發、分銷和相關人員參與與不斷發展的醫療保健模式保持一致。

針對行業領導者的實際建議著重於使產品開發、商業性執行和營運系統與不斷變化的用戶和政策實際情況相適應。首先，應優先考慮能夠減輕使用者負擔並提高用藥依從性的開發路徑，例如長效製劑和便捷的給藥系統，同時確保臨床和安全性指標能夠滿足患者的多樣化需求。其次，應透過供應商多元化、區域化生產以及確保價格和銷售在政策波動下保持穩定的合約機制，來增強供應鏈的韌性。

為了確保分析的嚴謹性，我們採用了一種透明的混合方法研究途徑，結合了對主要相關人員的訪談、對監管和臨床證據的審查以及專家檢驗。

本調查方法採用混合方法，確保研究在臨床、監管和商業領域均具有深度和相關性。主要調查包括對臨床醫生、採購負責人和保險公司進行結構化訪談，以獲取關於處方行為、採購限制和准入障礙的第一手觀點。次要調查包括對監管指南、臨床文獻和公共聲明進行全面審查，以驗證和補充主要調查的結果。

本文概述了將臨床創新、分銷演變和供應韌性聯繫起來的策略挑戰，以促進荷爾蒙避孕藥的獲取和分銷。

總之，荷爾蒙避孕藥正處於影響其取得和分銷的臨床創新、不斷演變的醫療服務模式以及政策趨勢的交匯點。長效和以使用者為中心的給藥方式正日益普及，而數位化管道和醫療專業人員教育正在改變傳統的分銷和諮詢模式。同時，貿易政策的變化和供應鏈壓力凸顯了製定具有韌性的籌資策略和提升區域營運能力的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以避孕方法分類的荷爾蒙避孕藥市場

  • 植入
    • 雙叉植入
    • 單桿植入
  • 注射式避孕藥
    • 長效型Medroxyprogesterone
    • 去甲睾酮庚酸酯
  • 避孕器
  • 口服避孕藥
    • 複方口服避孕藥
    • 僅含黃體素的避孕藥
  • 經皮貼劑
  • 陰道環
    • 長期使用戒指
    • 月環

第9章：依荷爾蒙成分分類的荷爾蒙避孕藥市場

  • 荷爾蒙避孕藥
  • 僅含黃體素的避孕藥

第10章：荷爾蒙避孕藥市場：依銷售管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：荷爾蒙避孕藥市場：以最終用戶分類

  • 診所
    • 私人診所
    • 公立診所
  • 家庭醫療保健
  • 醫院

第12章：荷爾蒙避孕藥市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：荷爾蒙避孕藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：荷爾蒙避孕藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國荷爾蒙避孕藥市場

第16章：中國荷爾蒙避孕藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Allergan plc
  • Bayer AG
  • Cipla Limited
  • Gedeon Richter plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4103B31E0668

The Hormonal Contraceptives Market was valued at USD 18.65 billion in 2025 and is projected to grow to USD 20.17 billion in 2026, with a CAGR of 9.01%, reaching USD 34.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.65 billion
Estimated Year [2026] USD 20.17 billion
Forecast Year [2032] USD 34.14 billion
CAGR (%) 9.01%

Contextualizing clinical, regulatory, and access-driven forces shaping the hormonal contraceptives landscape to guide executive decision-making and strategic priorities

The introduction frames the current hormonal contraceptives landscape by situating clinical innovation, user preferences, regulatory dynamics, and supply chain complexity within an integrated perspective tailored for senior stakeholders. Advances in long-acting reversible contraceptives alongside renewed emphasis on contraceptive choice and access have reshaped clinical pathways and procurement priorities. At the same time, shifting reimbursement policies and evolving guidance from regulatory authorities have altered approval timelines and commercial pathways for both incremental and novel products.

Consequently, leaders must consider not only product attributes but also the broader ecosystem that governs adoption, including provider education, digital channels for user engagement, and distribution resilience. This summary synthesizes cross-functional signals to clarify where clinical efficacy, patient-centered design, and operational readiness intersect. By aligning strategic priorities with these systemic trends, organizations can better anticipate adoption hurdles, optimize commercialization sequencing, and strengthen stakeholder partnerships that underpin sustainable growth in contraceptive provision.

How advancements in formulations, delivery systems, digital care pathways, and equity-driven policy shifts are collectively reshaping contraceptive provision and adoption trends

Transformative shifts in the hormonal contraceptives landscape reflect converging innovations in formulation, delivery, and service models that are changing how contraceptive care is accessed and delivered. Long-acting methods have gained traction as providers seek to reduce user burden and increase adherence, while next-generation formulations and novel delivery platforms seek to balance efficacy with tolerability. Parallel to product innovation, digitization of care pathways and telehealth-enabled prescribing have expanded points of access, reshaping patient journeys and altering the role that traditional pharmacy and clinic channels play in initiation and follow-up.

In addition, heightened attention to reproductive autonomy and equity has prompted policy shifts and funding reallocations that influence procurement and public health programming. Supply chain resilience has become a competitive differentiator, as manufacturers and distributors respond to geopolitical pressures and raw material constraints with inventory strategies and diversified sourcing. Taken together, these dynamics are producing a more user-centric, technology-enabled, and supply-conscious environment that requires nimble commercialization models and closer collaboration across clinical, regulatory, and commercial functions.

Assessing how 2025 tariff policy shifts in the United States catalyzed sourcing diversification, regional production investments, and procurement adaptations across supply chains

The introduction of tariffs in the United States in 2025 has had a multi-dimensional influence on the contraceptive supply chain, procurement practices, and commercial prioritization. Tariff-driven cost pressures have prompted manufacturers and distributors to reassess sourcing strategies, accelerating efforts to localize certain manufacturing steps, diversify supplier bases, and renegotiate supplier contracts to preserve margins without compromising product quality. As a result, some firms have prioritized investments in regional production capacity and bi-lateral supplier relationships to mitigate exposure to trade policy volatility.

Moreover, procurement entities and institutional buyers have adapted by revising purchasing cycles and inventory buffers to manage pricing uncertainty. This has impacted negotiation dynamics between suppliers and large purchasers, with increased emphasis on total cost of ownership, contracted price stability, and supply guarantees. Regulatory teams have also observed administrative effects as cost adjustments ripple through reimbursement discussions and tenders. While tariffs are one factor among many shaping commercial choices, they have acted as a catalyst for operational resilience strategies and accelerated localization considerations that will influence sourcing roadmaps and supplier selection for the foreseeable future.

Detailed segmentation-driven perspectives linking contraceptive type, hormonal composition, distribution channels, and end-user settings to inform prioritization and commercialization

Segmentation insights reveal where product attributes, hormonal composition, distribution channels, and end-user settings intersect to shape adoption and program design. Based on contraceptive type, the landscape includes implants, injectable contraceptives, intrauterine devices, oral contraceptives, transdermal patches, and vaginal rings; within implants, distinctions between double-rod and single-rod designs drive different insertion workflows and provider training needs, while injectable contraceptives divide into depot medroxyprogesterone acetate and norethisterone enanthate formulations that differ in dosing intervals and administration settings. Oral contraceptives bifurcate into combined oral contraceptives and progestin-only pills with distinct prescribing considerations, and vaginal rings are differentiated by extended-use and monthly ring options that carry divergent adherence and counseling implications.

Based on hormonal composition, the field separates into combined hormonal contraceptives and progestin-only contraceptives, a partition that matters clinically for contraindications, side-effect profiles, and patient selection. When viewed through the lens of sales channel, hospital pharmacies, online pharmacies, and retail pharmacies each present unique distribution economics, compliance requirements, and opportunities for digital engagement. Finally, based on end user, clinics, home healthcare, and hospitals represent varied points of care; clinics themselves divide into private and public clinics, creating distinct procurement pathways and payer interactions. Together, these segment dimensions inform product development priorities, clinical training investments, and channel strategies that align with both user preferences and provider workflows.

Examining how regional regulatory diversity, procurement models, and digital adoption across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated strategic responses

Regional dynamics demonstrate differentiated demand drivers, regulatory frameworks, and distribution challenges that shape strategic priorities across geographies. In the Americas, payer structures, public health programs, and private provider networks interact to influence uptake patterns and procurement models, with particular attention to reproductive health policy shifts that affect access and funding flows. The Europe, Middle East & Africa region presents a heterogeneous regulatory mosaic, where regulatory harmonization efforts coexist with varied reimbursement landscapes and infrastructure constraints that influence product selection and implementation strategies. In Asia-Pacific, rapid urbanization, digital health adoption, and manufacturing capacity expansion have created both commercial opportunities and operational complexities, as firms navigate diverse regulatory expectations and local market entry requirements.

Consequently, regional strategies must balance global product platforms with tailored approaches to distribution, pricing, and provider engagement. Cross-border logistics considerations and regional manufacturing investments have become increasingly relevant to maintain continuity of supply and competitive positioning. By mapping clinical, regulatory, and commercial levers region by region, organizations can prioritize investments that align with local access priorities while leveraging scale where regulatory convergence or manufacturing synergies exist.

How product differentiation, partnership strategies, and operational resilience define competitive positioning among established and emerging contraceptive innovators

Competitive insights highlight how established pharmaceutical firms and emerging specialists are responding across product innovation, supply chain resilience, and go-to-market strategies. Leading companies are investing in formulation improvements and differentiated delivery mechanisms to address tolerability and adherence, while newer entrants and niche players focus on specialized platforms such as extended-duration rings or next-generation subdermal devices. Partnerships and licensing arrangements have become tactical levers to accelerate time-to-clinic and broaden product portfolios without bearing the full cost of development.

Operationally, firms are strengthening supplier diversification and pursuing regional manufacturing or contract manufacturing arrangements to reduce exposure to trade disruptions. Commercially, there is an increased emphasis on provider education, digital engagement tools, and value-based contracting to demonstrate outcomes and secure formulary placement. At the same time, privacy, pharmacovigilance, and post-market surveillance have escalated in importance, prompting investments in real-world evidence generation and patient-reported outcomes programs. Together, these initiatives reflect a competitive environment where clinical differentiation, operational robustness, and evidence-driven commercialization determine sustained advantage.

Practical strategic priorities and operational measures industry leaders should adopt to align product development, distribution, and stakeholder engagement with evolving care models

Actionable recommendations for industry leaders focus on aligning product development, commercial execution, and operational systems to emergent user and policy realities. First, prioritize development pathways that reduce user burden and improve adherence, such as longer-acting formulations and intuitive delivery systems, while ensuring that clinical and safety profiles meet diverse patient needs. Second, strengthen supply chain resilience through supplier diversification, regional manufacturing options, and contractual mechanisms that provide price and volume stability under policy shifts.

Third, invest in multi-channel distribution strategies that integrate hospital pharmacies, retail and online pharmacies, and telehealth-enabled prescribing to broaden access and streamline patient journeys. Fourth, enhance provider and payer engagement through evidence packages that emphasize real-world outcomes, cost-effectiveness, and implementation support. Finally, embed equity and access objectives into product and commercial planning to address disparities in contraceptive access. Implementing these recommendations requires coordinated governance across R&D, regulatory, supply chain, and commercial functions to translate strategic intent into measurable outcomes.

Transparent mixed-methods research approach integrating primary stakeholder interviews, regulatory and clinical evidence review, and expert validation to ensure analytical rigor

The research methodology combined a mixed-methods approach to ensure depth and validity across clinical, regulatory, and commercial domains. Primary research included structured interviews with clinicians, procurement professionals, and payers to capture firsthand perspectives on prescribing behaviors, procurement constraints, and access barriers. Secondary research entailed a comprehensive review of regulatory guidance, clinical literature, and public policy statements to triangulate primary findings and provide contextual grounding.

Data synthesis emphasized cross-validation, whereby qualitative insights informed the interpretation of regulatory and operational signals, and documentary evidence corroborated recurring themes. Expert review sessions with clinical and supply chain specialists refined assumptions and clarified technical implications. Transparency was maintained regarding sources of evidence and analytical assumptions, and known limitations-such as jurisdictional heterogeneity in regulatory rules and evolving tariff landscapes-were explicitly documented to guide interpretation and application of findings.

Summarizing strategic imperatives that connect clinical innovation, distribution evolution, and supply resilience to advance access and adoption of hormonal contraceptives

In conclusion, hormonal contraceptives are situated at the intersection of clinical innovation, evolving care delivery models, and policy dynamics that together shape access and adoption. Long-acting and user-centric delivery approaches are gaining momentum, while digital channels and provider education are altering traditional distribution and counseling models. Concurrently, trade policy shifts and supply chain pressures underscore the need for resilient sourcing strategies and regional operational capacity.

Decision-makers who align product development with provider workflows, invest in diversified distribution channels, and prioritize evidence generation for real-world outcomes will be best positioned to respond to both clinical and commercial imperatives. By integrating these strategic priorities with operational safeguards and stakeholder engagement plans, organizations can more effectively support access, drive adoption, and contribute to improved reproductive health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hormonal Contraceptives Market, by Contraceptive Type

  • 8.1. Implants
    • 8.1.1. Double-Rod Implants
    • 8.1.2. Single-Rod Implants
  • 8.2. Injectable Contraceptives
    • 8.2.1. Depot Medroxyprogesterone Acetate
    • 8.2.2. Norethisterone Enanthate
  • 8.3. Intrauterine Devices
  • 8.4. Oral Contraceptives
    • 8.4.1. Combined Oral Contraceptives
    • 8.4.2. Progestin-Only Pills
  • 8.5. Transdermal Patches
  • 8.6. Vaginal Rings
    • 8.6.1. Extended-Use Rings
    • 8.6.2. Monthly Rings

9. Hormonal Contraceptives Market, by Hormonal Composition

  • 9.1. Combined Hormonal Contraceptives
  • 9.2. Progestin-Only Contraceptives

10. Hormonal Contraceptives Market, by Sales Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Hormonal Contraceptives Market, by End User

  • 11.1. Clinics
    • 11.1.1. Private Clinics
    • 11.1.2. Public Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Hormonal Contraceptives Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hormonal Contraceptives Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hormonal Contraceptives Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Hormonal Contraceptives Market

16. China Hormonal Contraceptives Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Allergan plc
  • 17.6. Bayer AG
  • 17.7. Cipla Limited
  • 17.8. Gedeon Richter plc
  • 17.9. Johnson & Johnson
  • 17.10. Merck & Co., Inc.
  • 17.11. Pfizer Inc.
  • 17.12. Sun Pharmaceutical Industries Ltd.
  • 17.13. Teva Pharmaceutical Industries Ltd.
  • 17.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HORMONAL CONTRACEPTIVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HORMONAL CONTRACEPTIVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 179. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 180. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 209. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)